Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

17.59 -0.12 (-0.71%)
Streaming Delayed Price Updated: 12:39 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 445,558
Open 17.70
Bid (Size) 17.58 (6)
Ask (Size) 17.59 (10)
Prev. Close 17.71
Today's Range 17.52 - 17.80
52wk Range 14.87 - 23.40
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
 
Via Benzinga
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
From Exelixis, Inc.
Via Business Wire

Performance

YTD
+7.88%
+7.88%
1 Month
+13.60%
+13.60%
3 Month
+7.75%
+7.75%
6 Month
-15.17%
-15.17%
1 Year
-1.87%
-1.87%

More News

Read More
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
Via Benzinga
6 Analysts Have This to Say About Exelixis
Via Benzinga
Is Exelixis Stock a Buy Now?
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Where Exelixis Stands With Analysts
Via Benzinga
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
Via MarketBeat
Exposures COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Via The Motley Fool
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
Via The Motley Fool
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Via Benzinga
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
3 Stocks to Buy Hand Over Fist in December
Via The Motley Fool
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
Via The Motley Fool
The Smartest Stocks to Buy With $20 Right Now
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less than $20
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.